In Its Second Biotech Deal In Three Months, Ranbaxy Signs Pact With Pfenex For An Undisclosed Biosimilar
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Moving one step closer to realizing its ambitions in the fast-emerging biosimilars space, Daiichi Sankyo's Indian arm Ranbaxy signed a development deal with the San Diego-based Pfenex, a spin-off of the Dow Chemical Company
You may also be interested in...
Ranbaxy Buys Biovel For An Entry Into Vaccines and Biotherapeutics
MUMBAI - Lucrative opportunities in the business of vaccines has attracted one more big drug maker. India's Ranbaxy clinched a deal with Bangalore-based Biovel in an asset buyout that is expected to help it gain foothold in a market that reached $700 million in India and $21 billion in worldwide sales in 2008
Indian Tribunal Back Zenotech, Daiichi Sankyo's Struggle On Open Offer Price Continues
MUMBAI - Daiichi Sankyo's year-long struggle to wrest control of India's biotech and oncology start-up Zenotech Labs received yet another setback as the Securities Appellate Tribunal backed the founder promoters of the Hyderabad-based company led by Jayaram Chigurupati and asked the Japanese company to increase the offer price for the shares to further bolster its shareholding
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).